Cushman & Wakefield (NYSE:CWK – Get Free Report) issued its quarterly earnings data on Monday. The company reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.02, Briefing.com reports. The business had revenue of $2.34 billion for the quarter, compared to analysts’ expectations of $1.61 billion. Cushman & Wakefield had a net margin of 0.22% and a return on equity of 12.08%. The company’s revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.21 earnings per share.
Cushman & Wakefield Stock Up 15.5 %
CWK stock opened at $15.18 on Wednesday. The firm has a market cap of $3.48 billion, a PE ratio of 189.69 and a beta of 1.30. Cushman & Wakefield has a 12 month low of $7.28 and a 12 month high of $15.98. The company has a debt-to-equity ratio of 1.83, a current ratio of 1.21 and a quick ratio of 1.21. The firm has a 50 day simple moving average of $13.13 and a 200 day simple moving average of $11.93.
Wall Street Analysts Forecast Growth
Several research firms have commented on CWK. Raymond James boosted their price target on shares of Cushman & Wakefield from $14.00 to $16.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. JPMorgan Chase & Co. upped their target price on Cushman & Wakefield from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $12.80.
Cushman & Wakefield Company Profile
Cushman & Wakefield plc, together with its subsidiaries, provides commercial real estate services under the Cushman & Wakefield brand in the United States, Australia, the United Kingdom, and internationally. The company operates through Americas; Europe, Middle East and Africa; and Asia Pacific segments.
Featured Stories
- Five stocks we like better than Cushman & Wakefield
- Financial Services Stocks Investing
- Discover the 3 Best-Performing Biotech IPO Stocks of 2024
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Hims & Hers: Why This Healthcare Stock’s Growth Makes It a Buy
- Best Stocks Under $5.00
- Astera Labs’ Big Stock Jump: Can the Growth Be Sustained?
Receive News & Ratings for Cushman & Wakefield Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cushman & Wakefield and related companies with MarketBeat.com's FREE daily email newsletter.